NCT03307759

Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Peter MacCallum Cancer Centre, Australia · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This investigator driven Phase Ib study will examine the safety, efficacy and biological effects of two schedules of pembrolizumab, an antibody targeted against anti-programmed cell death 1 (PD-1), which will be given either before or after stereotactic ablative body radiotherapy (SABR) for metastatic NSCLC.

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Pembrolizumab
RADIATION	Radiotherapy (SABR)	Radiotherapy

Timeline

• Start date: 2017-12-07
• Primary completion: 2022-01-31
• Completion: 2022-01-31
• First posted: 2017-10-12
• Last updated: 2025-09-15
• Results posted: 2025-09-15

Locations

1 site across 1 country: Australia

Regulatory

• FDA-regulated drug study